Abstract 63P
Background
Breast cancer is one of the cancers with highest incidence with more than two million people diagnosed in 2018 and causes more than 600.000 deaths. The big number of deaths are mostly due to breast cancer metastasis. Butterfly pea flower (Clitoria ternatea Linn.) is a medicinal plant which is known to have a wide range of pharmacological activities because it contains many kinds of active substances one of which is quercetin known to have anti-breast cancer activity especially metastasis through inhibition of NF-κB (nuclear factor kappa B). Those transcription factors play an important role in the metastasis process in HER2-positive breast cancer type. The butterfly pea flower activity as an antimetastatic agent in MCF-7 HER2-positive has not been well understood. The aim of the study was to find out the antimetastatic activity of butterfly pea flower extract on MCF-7 HER-positive breast cancer cell line.
Methods
Maceration process using 96% ethanol to obtain the crude extract, thin layer chromatography (TLC) to see the phytochemical profile of butterfly pea leaf extract, MTT assay to determine the IC50 using log probit analysis as a reference for the next test which is scratch wound healing assay to assess the effect of butterfly pea leaf extract on the migration of 4T1 breast cancer cell line.
Results
Butterfly pea flower extraction using maceration obtains a 18.06% yield. Phytochemical study using thin layer chromatography suggested the Rf of crude extract had the same Rf with quercetin standard which is 0.57 so it was proven that the crude extract contained quercetin. The MTT assay and log probit analysis showed the IC50 of butterfly pea crude extract was 862 μg/mL. The scratch wound healing assay using concentrations below IC50 showed 50% of cell migration activity of the MCF-7 HER2-positive was inhibited in 24 hours interval by 380 μg/mL crude extract and in 48 hours interval with 500 μg/mL of crude extract was able to prevent the scratch closure. Statistical analysis using SPSS 16.0 showed that the crude extract can significantly suppressed the migration of the cancer cell.
Conclusions
Butterfly pea flower extract has an antimetastatic activity to MCF-7 HER2-positive breast cancer cell line in-vitro.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
UGM.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - A multicenter, prospective study of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer
Presenter: Yi-Hui Tang
Session: e-Poster Display Session
155P - Surgical outcomes and technical performance of robotic versus laparoscopic total gastrectomy for gastric cancer: A prospective comparative study FUGES-014
Presenter: Hua-Gen Wang
Session: e-Poster Display Session
156P - Safety and feasibility of laparoscopic spleen-preserving splenic hilar lymphadenectomy during total gastrectomy for advanced proximal gastric cancer: A randomized clinical trial
Presenter: Jian-Xian Lin
Session: e-Poster Display Session
157P - Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
Presenter: Amy Prawira
Session: e-Poster Display Session
158P - A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX study): Final report
Presenter: Atsuo Takashima
Session: e-Poster Display Session
159P - Open surgery can improve the 3-year postoperative survival in some patients with advanced gastric cancer compared with laparoscopic surgery: A multicenter, propensity score matching, in-depth analysis
Presenter: Ze-Ning Huang
Session: e-Poster Display Session
160P - Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Ning Li
Session: e-Poster Display Session
161P - Adjuvant tegafur/gimeracil/oteracil (S-1) versus platinum-based chemotherapies for resectable gastric cancer: Real-world experience and a propensity score matching analysis
Presenter: Chih Chieh Yen
Session: e-Poster Display Session
162P - Evaluation of neutrophil/lymphocyte ratio (NLR) in monitoring anastomotic leakage after radical total gastrectomy for gastric cancer
Presenter: Ru-Hong Tu
Session: e-Poster Display Session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session